NASDAQ:AXDX - Accelerate Diagnostics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.50
  • Forecasted Upside: 115.78 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.11
▲ +0.05 (0.62%)
1 month | 3 months | 12 months
Get New Accelerate Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXDX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.50
▲ +115.78% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Accelerate Diagnostics in the last 3 months. The average price target is $17.50, with a high forecast of $20.00 and a low forecast of $15.00. The average price target represents a 115.78% upside from the last price of $8.11.
Buy
The current consensus among 3 investment analysts is to buy stock in Accelerate Diagnostics. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2020Piper SandlerLower Price TargetOverweight$18.00 ➝ $15.00High
i
10/7/2020BTIG ResearchInitiated CoverageNeutralMedium
i
8/10/2020Piper SandlerBoost Price TargetOverweight$14.00 ➝ $18.00Medium
i
8/7/2020Craig HallumUpgradeHold ➝ Buy$20.00High
i
5/11/2020Piper SandlerLower Price TargetOverweight$16.00 ➝ $14.00Medium
i
Rating by William Quirk at Piper Sandler
1/14/2020Piper SandlerBoost Price TargetOverweight$16.00 ➝ $20.00High
i
9/27/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$16.00High
i
8/9/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ Positive$22.00 ➝ $19.00High
i
5/12/2019BTIG ResearchReiterated RatingHoldHigh
i
2/20/2019Piper Jaffray CompaniesBoost Price TargetIn-Line ➝ Overweight$22.00High
i
1/11/2019Piper Jaffray CompaniesLower Price TargetOverweight$17.00High
i
11/7/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $16.00High
i
8/7/2018Piper Jaffray CompaniesReiterated RatingBuy$24.00High
i
5/24/2018Craig HallumInitiated CoverageHold$25.00Medium
i
2/18/2018BTIG ResearchReiterated RatingHoldMedium
i
12/13/2017BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
7/12/2017BTIG ResearchReiterated RatingBuy ➝ Buy$34.00High
i
6/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00 ➝ $32.00Low
i
5/17/2017BTIG ResearchReiterated RatingBuy$34.00High
i
8/25/2016BTIG ResearchUpgradeNeutral ➝ BuyN/A
i
Rating by Karen Koski at BTIG Research
8/9/2016BTIG ResearchReiterated RatingBuy$26.00N/A
i
Rating by Karen Koski at BTIG Research
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$17.00 ➝ $25.00N/A
i
Rating by Tycho Peterson at JPMorgan Chase & Co.
6/15/2016BTIG ResearchReiterated RatingBuy$26.00N/A
i
Rating by Karen Koski at BTIG Research
5/16/2016Piper Jaffray CompaniesReiterated RatingOverweight$25.00N/A
i
Rating by William Quirk at Piper Jaffray Companies
5/15/2016BTIG ResearchReiterated RatingBuy$26.00N/A
i
Rating by Karen Koski at BTIG Research
(Data available from 4/19/2016 forward)
Accelerate Diagnostics logo
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Read More

Today's Range

Now: $8.11
$7.70
$8.11

50 Day Range

MA: $9.03
$7.99
$10.29

52 Week Range

Now: $8.11
$6.82
$19.11

Volume

152,143 shs

Average Volume

535,929 shs

Market Capitalization

$496.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Accelerate Diagnostics?

The following equities research analysts have issued stock ratings on Accelerate Diagnostics in the last twelve months: BTIG Research, Craig Hallum, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for AXDX.

What is the current price target for Accelerate Diagnostics?

2 Wall Street analysts have set twelve-month price targets for Accelerate Diagnostics in the last year. Their average twelve-month price target is $17.50, suggesting a possible upside of 115.8%. Craig Hallum has the highest price target set, predicting AXDX will reach $20.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $15.00 for Accelerate Diagnostics in the next year.
View the latest price targets for AXDX.

What is the current consensus analyst rating for Accelerate Diagnostics?

Accelerate Diagnostics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXDX will outperform the market and that investors should add to their positions of Accelerate Diagnostics.
View the latest ratings for AXDX.

What other companies compete with Accelerate Diagnostics?

How do I contact Accelerate Diagnostics' investor relations team?

Accelerate Diagnostics' physical mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company's listed phone number is 520-365-3100 and its investor relations email address is [email protected] The official website for Accelerate Diagnostics is acceleratediagnostics.com.